Do analysts recommend LIMN or NEUP?

Neuphoria Therapeutics has a consensus price target of $21.00, suggesting a potential upside of 431.65%. Given Neuphoria Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Neuphoria Therapeutics is more favorable than Liminatus Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Neuphoria Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is LIMN or NEUP more profitable?

Liminatus Pharma's return on equity of 0.00% beat Neuphoria Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Liminatus Pharma N/A N/A -299.79% Neuphoria Therapeutics N/A -76.93% -54.76%

Do analysts recommend LIMN or LGVN?

Longeveron has a consensus target price of $5.50, suggesting a potential upside of 656.43%. Given Longeveron's stronger consensus rating and higher possible upside, analysts plainly believe Longeveron is more favorable than Liminatus Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Longeveron 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Do analysts rate LIMN or CLRB?

Cellectar Biosciences has a consensus price target of $11.00, suggesting a potential upside of 336.51%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Cellectar Biosciences is more favorable than Liminatus Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cellectar Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80

Which has higher valuation and earnings, LIMN or CLRB?

Cellectar Biosciences is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liminatus Pharma N/A N/A -$10.21M -$0.44 N/A Cellectar Biosciences N/A N/A -$21.79M -$6.66 N/A

Is LIMN or CLRB more profitable?

Liminatus Pharma's return on equity of 0.00% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Liminatus Pharma N/A N/A -299.79% Cellectar Biosciences N/A -349.24% -153.18%

Do analysts recommend GRDX or LIMN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is GRDX or LIMN more profitable?

Liminatus Pharma's return on equity of 0.00% beat Entero Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Entero Therapeutics N/A -49.81% -11.02% Liminatus Pharma N/A N/A -299.79%

Do analysts prefer KZIA or LIMN?

Novogen presently has a consensus price target of $25.80, indicating a potential upside of 115.00%. Given Novogen's stronger consensus rating and higher probable upside, equities research analysts plainly believe Novogen is more favorable than Liminatus Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novogen 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, KZIA or LIMN?

Liminatus Pharma has lower revenue, but higher earnings than Novogen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $42K 472.29 -$13.41M N/A N/A Liminatus Pharma N/A N/A -$10.21M -$0.44 N/A

Is KZIA or LIMN more profitable?

Company Net Margins Return on Equity Return on Assets Novogen N/A N/A N/A Liminatus Pharma N/A N/A -299.79%

Liminatus Pharma (LIMN) Competitors

$0.10 -0.01 (-11.17%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$0.11 +0.00 (+1.90%)

As of 04:33 AM Eastern

Compare

LIMN vs. NEUP, LGVN, CLRB, GRDX, and KZIA

Should you buy Liminatus Pharma stock or one of its competitors? MarketBeat compares Liminatus Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Liminatus Pharma include Neuphoria Therapeutics (NEUP), Longeveron (LGVN), Cellectar Biosciences (CLRB), Entero Therapeutics (GRDX), and Novogen (KZIA).

How does Liminatus Pharma compare to Neuphoria Therapeutics?

Liminatus Pharma (NASDAQ:LIMN) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk.

Neuphoria Therapeutics has a consensus price target of $21.00, suggesting a potential upside of 431.65%. Given Neuphoria Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Neuphoria Therapeutics is more favorable than Liminatus Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Liminatus Pharma's return on equity of 0.00% beat Neuphoria Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liminatus Pharma	N/A	N/A	-299.79%
Neuphoria Therapeutics	N/A	-76.93%	-54.76%

In the previous week, Neuphoria Therapeutics had 1 more articles in the media than Liminatus Pharma. MarketBeat recorded 1 mentions for Neuphoria Therapeutics and 0 mentions for Liminatus Pharma. Liminatus Pharma's average media sentiment score of 0.00 equaled Neuphoria Therapeutics'average media sentiment score.

Company	Overall Sentiment
Liminatus Pharma	Neutral
Neuphoria Therapeutics	Neutral

15.9% of Neuphoria Therapeutics shares are held by institutional investors. 19.4% of Liminatus Pharma shares are held by insiders. Comparatively, 1.5% of Neuphoria Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Neuphoria Therapeutics has higher revenue and earnings than Liminatus Pharma. Neuphoria Therapeutics is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liminatus Pharma	N/A	N/A	-$10.21M	-$0.44	N/A
Neuphoria Therapeutics	$15.65M	1.36	-$370K	-$11.06	N/A

Liminatus Pharma has a beta of 5.35, meaning that its share price is 435% more volatile than the broader market. Comparatively, Neuphoria Therapeutics has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market.

Summary

Neuphoria Therapeutics beats Liminatus Pharma on 8 of the 13 factors compared between the two stocks.

How does Liminatus Pharma compare to Longeveron?

Liminatus Pharma (NASDAQ:LIMN) and Longeveron (NASDAQ:LGVN) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Longeveron has a consensus target price of $5.50, suggesting a potential upside of 656.43%. Given Longeveron's stronger consensus rating and higher possible upside, analysts plainly believe Longeveron is more favorable than Liminatus Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Longeveron	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Liminatus Pharma has a beta of 5.35, indicating that its share price is 435% more volatile than the broader market. Comparatively, Longeveron has a beta of -0.31, indicating that its share price is 131% less volatile than the broader market.

10.0% of Longeveron shares are owned by institutional investors. 19.4% of Liminatus Pharma shares are owned by company insiders. Comparatively, 7.4% of Longeveron shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Liminatus Pharma has a net margin of 0.00% compared to Longeveron's net margin of -1,844.49%. Liminatus Pharma's return on equity of 0.00% beat Longeveron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liminatus Pharma	N/A	N/A	-299.79%
Longeveron	-1,844.49%	-202.41%	-140.67%

In the previous week, Longeveron had 1 more articles in the media than Liminatus Pharma. MarketBeat recorded 1 mentions for Longeveron and 0 mentions for Liminatus Pharma. Liminatus Pharma's average media sentiment score of 0.00 equaled Longeveron'saverage media sentiment score.

Company	Overall Sentiment
Liminatus Pharma	Neutral
Longeveron	Neutral

Liminatus Pharma has higher earnings, but lower revenue than Longeveron. Longeveron is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liminatus Pharma	N/A	N/A	-$10.21M	-$0.44	N/A
Longeveron	$1.20M	18.87	-$22.70M	-$1.13	N/A

Summary

Liminatus Pharma and Longeveron tied by winning 7 of the 14 factors compared between the two stocks.

How does Liminatus Pharma compare to Cellectar Biosciences?

Liminatus Pharma (NASDAQ:LIMN) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

In the previous week, Cellectar Biosciences had 4 more articles in the media than Liminatus Pharma. MarketBeat recorded 4 mentions for Cellectar Biosciences and 0 mentions for Liminatus Pharma. Cellectar Biosciences' average media sentiment score of 0.50 beat Liminatus Pharma's score of 0.00 indicating that Cellectar Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Liminatus Pharma	Neutral
Cellectar Biosciences	Neutral

Liminatus Pharma's return on equity of 0.00% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liminatus Pharma	N/A	N/A	-299.79%
Cellectar Biosciences	N/A	-349.24%	-153.18%

Cellectar Biosciences is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liminatus Pharma	N/A	N/A	-$10.21M	-$0.44	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A

Liminatus Pharma has a beta of 5.35, suggesting that its stock price is 435% more volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market.

Cellectar Biosciences has a consensus price target of $11.00, suggesting a potential upside of 336.51%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Cellectar Biosciences is more favorable than Liminatus Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

16.4% of Cellectar Biosciences shares are held by institutional investors. 19.4% of Liminatus Pharma shares are held by company insiders. Comparatively, 2.6% of Cellectar Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Cellectar Biosciences beats Liminatus Pharma on 8 of the 14 factors compared between the two stocks.

How does Liminatus Pharma compare to Entero Therapeutics?

Entero Therapeutics (NASDAQ:GRDX) and Liminatus Pharma (NASDAQ:LIMN) are related small-cap companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

12.3% of Entero Therapeutics shares are owned by institutional investors. 0.8% of Entero Therapeutics shares are owned by insiders. Comparatively, 19.4% of Liminatus Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Entero Therapeutics has a beta of 1.86, indicating that its share price is 86% more volatile than the broader market. Comparatively, Liminatus Pharma has a beta of 5.35, indicating that its share price is 435% more volatile than the broader market.

Entero Therapeutics has higher revenue and earnings than Liminatus Pharma. Entero Therapeutics is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	$40K	478.52	-$6.39M	-$1.88	N/A
Liminatus Pharma	N/A	N/A	-$10.21M	-$0.44	N/A

In the previous week, Entero Therapeutics' average media sentiment score of 0.00 equaled Liminatus Pharma'saverage media sentiment score.

Company	Overall Sentiment
Entero Therapeutics	Neutral
Liminatus Pharma	Neutral

Liminatus Pharma's return on equity of 0.00% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-49.81%	-11.02%
Liminatus Pharma	N/A	N/A	-299.79%

Summary

Liminatus Pharma beats Entero Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Liminatus Pharma compare to Novogen?

Novogen (NASDAQ:KZIA) and Liminatus Pharma (NASDAQ:LIMN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

30.9% of Novogen shares are owned by institutional investors. 1.0% of Novogen shares are owned by company insiders. Comparatively, 19.4% of Liminatus Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Novogen had 1 more articles in the media than Liminatus Pharma. MarketBeat recorded 1 mentions for Novogen and 0 mentions for Liminatus Pharma. Liminatus Pharma's average media sentiment score of 0.00 beat Novogen's score of -0.54 indicating that Liminatus Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Novogen	Negative
Liminatus Pharma	Neutral

Novogen presently has a consensus price target of $25.80, indicating a potential upside of 115.00%. Given Novogen's stronger consensus rating and higher probable upside, equities research analysts plainly believe Novogen is more favorable than Liminatus Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
Liminatus Pharma	N/A	N/A	-299.79%

Novogen has a beta of 2.16, suggesting that its stock price is 116% more volatile than the broader market. Comparatively, Liminatus Pharma has a beta of 5.35, suggesting that its stock price is 435% more volatile than the broader market.

Liminatus Pharma has lower revenue, but higher earnings than Novogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$42K	472.29	-$13.41M	N/A	N/A
Liminatus Pharma	N/A	N/A	-$10.21M	-$0.44	N/A

Summary

Novogen beats Liminatus Pharma on 7 of the 11 factors compared between the two stocks.

Get Liminatus Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LIMN vs. The Competition

Export

Metric	Liminatus Pharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.98M	$3.57B	$6.86B	$12.98B
Dividend Yield	N/A	3.77%	2.60%	9.79%
P/E Ratio	-0.24	7.68	280.40	25.25
Price / Sales	N/A	1,179.03	562.13	77.61
Price / Cash	N/A	103.01	71.79	50.79
Price / Book	-0.29	17.07	12.94	6.09
Net Income	-$10.21M	-$12.52M	$3.49B	$347.95M
7 Day Performance	2.84%	2.31%	2.42%	3.11%
1 Month Performance	-26.37%	-5.14%	-2.87%	-2.99%
1 Year Performance	-97.77%	52.14%	75.29%	20.51%

Liminatus Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LIMN Liminatus Pharma	0.1276 of 5 stars	$0.11 -11.2%	N/A	-97.9%	$5.98M	N/A	N/A	N/A
NEUP Neuphoria Therapeutics	2.255 of 5 stars	$3.82 +0.6%	$21.00 +449.2%	-48.0%	$20.65M	$15.65M	N/A	N/A
LGVN Longeveron	1.7166 of 5 stars	$0.66 +10.9%	$5.50 +733.3%	-53.1%	$20.50M	$1.20M	N/A	20	Positive News Upcoming Earnings
CLRB Cellectar Biosciences	3.8476 of 5 stars	$2.54 +2.2%	$11.00 +333.9%	-48.3%	$20.26M	N/A	N/A	10	Positive News Upcoming Earnings Gap Down
GRDX Entero Therapeutics	N/A	$2.93 +12.5%	N/A	N/A	$20.23M	$40K	N/A	9	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LIMN) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Liminatus Pharma (LIMN) Competitors

LIMN vs. NEUP, LGVN, CLRB, GRDX, and KZIA

How does Liminatus Pharma compare to Neuphoria Therapeutics?

Summary

How does Liminatus Pharma compare to Longeveron?

Summary

How does Liminatus Pharma compare to Cellectar Biosciences?

Summary

How does Liminatus Pharma compare to Entero Therapeutics?

Summary

How does Liminatus Pharma compare to Novogen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIMN vs. The Competition

Liminatus Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Liminatus Pharma (LIMN) Competitors

LIMN vs. NEUP, LGVN, CLRB, GRDX, and KZIA

How does Liminatus Pharma compare to Neuphoria Therapeutics?

Do analysts recommend LIMN or NEUP?

Is LIMN or NEUP more profitable?

Does the media prefer LIMN or NEUP?

Do institutionals & insiders believe in LIMN or NEUP?

Which has stronger earnings and valuation, LIMN or NEUP?

Which has more volatility & risk, LIMN or NEUP?

Summary

How does Liminatus Pharma compare to Longeveron?

Do analysts recommend LIMN or LGVN?

Which has more volatility & risk, LIMN or LGVN?

Do institutionals & insiders hold more shares of LIMN or LGVN?

Is LIMN or LGVN more profitable?

Does the media prefer LIMN or LGVN?

Which has better valuation and earnings, LIMN or LGVN?

Summary

How does Liminatus Pharma compare to Cellectar Biosciences?

Does the media prefer LIMN or CLRB?

Is LIMN or CLRB more profitable?

Which has higher valuation and earnings, LIMN or CLRB?

Which has more risk and volatility, LIMN or CLRB?

Do analysts rate LIMN or CLRB?

Do insiders and institutionals hold more shares of LIMN or CLRB?

Summary

How does Liminatus Pharma compare to Entero Therapeutics?

Do institutionals and insiders hold more shares of GRDX or LIMN?

Do analysts recommend GRDX or LIMN?

Which has more risk and volatility, GRDX or LIMN?

Which has higher earnings & valuation, GRDX or LIMN?

Does the media favor GRDX or LIMN?

Is GRDX or LIMN more profitable?

Summary

How does Liminatus Pharma compare to Novogen?

Do institutionals and insiders have more ownership in KZIA or LIMN?

Does the media favor KZIA or LIMN?

Do analysts prefer KZIA or LIMN?

Is KZIA or LIMN more profitable?

Which has more risk and volatility, KZIA or LIMN?

Which has stronger valuation & earnings, KZIA or LIMN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIMN vs. The Competition

Liminatus Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools